Report ID : 10079042 |
Published Date : 21 Oct 2022 |
Report Format : PDF,PPT |
Delivery Timeline :48-72 Business Hours
Global Robotic Grippers Industry was valued at USD 932 Million in the year 2019. Global Robotic Grippers Industry is further estimated to grow at a CAGR of 0.8% from 2019 to reach USD 986 Million by the year 2025. The Robotic Grippers is the most vital treatment for those patient which are experiencing bleeding issue, the blood thickening procedure get moderate or did not happens in patient because of which real medical problem can influence the body. The procedure of blood coagulating is constrained by platelets or thrombocytes, the insufficiency of platelets or thrombocytes in blood influence the patient amid medical procedure or any major or minor harm in which blood is left the body or any inner dying. The platelets which is in charge of thickening is made in bone marrow alongside other platelets. The patient which are experiencing endless invulnerable thrombocytopenia is otherwise called purpura as the wounds showed up on skin. The little bleeding spot are known as petechiae which look like a rash. The unending insusceptible thrombocytopenia which happens for the most part in grown-ups and last over a half year however now and again kids likewise influence with incessant invulnerable thrombocytopenia. Ladies has greater likelihood then men for getting influenced with endless safe thrombocytopenia.
The Robotic Grippers Industry is relied upon to have critical development, as the patient which experience the ill effects of unending safe thrombocytopenia need to confront many significant medical problem. The perpetual safe thrombocytopenia treatment is important to shield the patient from blood misfortune amid medical procedure or in any major or minor mishap. Interminable invulnerable thrombocytopenia treatment give sound way of life to the patient which are experiencing unending insusceptible thrombocytopenia and enable them to have ordinary way of life. The absence of mindfulness for determination of unending safe thrombocytopenia and mind-boggling expense of treatment for incessant invulnerable thrombocytopenia is the present deterrents for the present market of endless insusceptible thrombocytopenia treatment.
From 2023, however, market value will start declining due to the patent expiration and subsequent generic launch of Promacta, Nplate, and Roche’s Rituxan (rituximab). The declining treatment rate of paediatric Immune thrombocytopenia treatment patients, and the stagnant treatment paradigm caused by a lack of late-stage pipeline activities are also the major barriers of market growth.
Major market players in Robotic Grippers Industry are Amgen, Bristol-Myers Squibb, Eisai, Genosco, GlaxoSmithKline, Gliknik, Hansa, Hoffmann La-Roche, Immunomedics, Jiangsu Hengrui, Kyowa Hakko Kirin, Ligand Pharmaceuticals, Merck & Co., Momenta, Novartis, and PBM Capital.
Robotic Grippers Industry Segmentation:
Robotic Grippers Industry Overview, By Treatment Type
Drug Based Treatment
Splenectomy Treatment
Other Treatment
Robotic Grippers Industry Overview, By End-User
• Hospitals
• Ambulatory Surgery Centre
• Emergency Centre
• Others
Robotic Grippers Industry Overview, By Region
North America
• USA
• Canada
Europe
• Germany
• U.K.
• France
• Italy
• Rest of Europe
APAC
• China
• India
• Japan
• Rest of Asia-Pacific
RoW
• Latin America
• Middle East & Africa
